Gingival hyperplasia is a common occurrence in transplant recipients who are taking cyclosporine. This condition can be complicated when calcium channel blockers or phenytoin are added to the armamentarium of medications; it can be painful and may interfere with eating, speech, and appearance. Multiple mechanisms exist for gingival overgrowth. Prevention with appropriate oral hygiene appears important in controlling the inflammatory component and decreasing the severity of the overgrowth. Patients must be aware of the potential for the development of gingival hyperplasia and must follow up with regular professional cleanings. If the overgrowth persists, treatment options should be discussed between patients and their physician. Conversion from cyclosporine to tacrolimus, treatment with antibiotic therapy, and surgical excision or laser therapy are all potential therapies to consider.
Get full access to this article
View all access options for this article.
References
1.
SteeleRMSchunaAASchreiberRT. Calcium antagonist-induced gingival hyperplasia. Ann Intern Med.1994;120: 663–664.
2.
FattoreLStableinMBredfeldtGSemlaTMoranMDoherty-GreenbergJM. Gingival hyperplasia: A side effect of nifedipine and diltiazem. Spec Care Dentist.1991;11:107–109.
3.
MillerCSDammDD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol.1992;63:453–456.
4.
JorgensenMG. Prevalence of amlodipine-related gingival hyperplasia. J Periodontol.1997;68:676–678.
5.
LombardiTFiore-DonnoGBelserUDi FeliceR. Felodipine-induced gingival hyperplasia: A clinical and histologic study. J Oral Pathol Med.1991;20:89–92.
6.
BrownRSSeinPCorioRBottomleyWK. Nitrendipine-induced gingival hyperplasia: First case report. Oral Surg Oral Med Oral Pathol.1990;70:593–596.
ButlerRTKalkwarfKLKaldahlWB. Drug-induced gingival hyperplasia: Phenytoin, cyclosporine, and nifedipine. J Am Dent Assoc.1987;114:56–60.
9.
MerawSJSheridanPJ. Medically induced gingival hyperplasia. Mayo Clin Proc.1998;73:1196–1199.
10.
LaupacisA, for the Canadian transplant study group. Complications of CyA: A comparison to azathioprine. Transplant Proc.1983;15:2748–2753.
11.
AllmanSDMcWHorterAGSealeNS. Evaluation of cyclosporin-induced gingival overgrowth in the pediatric transplant patient. Pediatr Dent.1994;16:36–40.
12.
HeftiAFEshenaurAEHassellTMStoneC. Gingival overgrowth in cyclosporine A treated multiple sclerosis patients. J Periodontol.1994;65:744–749.
13.
David-NetoELemosFBFurusawaEA. Impact of cyclosporine A pharmacokinetics on the presence of side effects in pediatric renal transplantation. J Am Soc Nephrol.2000;11:343–349.
14.
BrownRSBeaverWTBottomleyWK. On the mechanism of drug-induced gingival hyperplasia. J Oral Pathol Med.1991;20:201–209.
15.
ThomasDWNewcombeRGOsborneGR. Risk factors in the development of cyclosporine-induced gingival overgrowth. Transplantation.2000;69:522–526.
16.
PernuHEKnuuttilaMLEHuttunenKRHTiilikainenAS. Drug-induced gingival overgrowth and class II major histo-compatibility antigens. Transplantation.1994;57:1811–1823.
17.
VargaELennonMAMairLH. Pre-transplant gingival hyperplasia predicts severe cyclosporin-induced gingival overgrowth in renal transplant patients. J Clin Periodontol.1998;25:225–230.
18.
SeymourRAThomasonJMEllisJS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol.1996;23:165–175.
19.
ThomasonJMSeymourRARiceN. The prevalence and severity of cyclosporin and nifedipine-induced gingival overgrowth. J Clin Periodontol.1993;20:37–40.
20.
AtillaGKutukculerN. Crevicular fluid interleukin-1β, tumor necrosis factor-α, and interleukin-6 levels in renal transplant patients receiving cyclosporine A. J Periodontol.1998;69:784–790.
21.
MyrillasTTLindenGJMarleyJJIrwinCR. Cyclosporin A regulates interleukin-1β and interleukin-6 expression in gingiva: Implications for gingival overgrowth. J Periodontol.1999;70:294–300.
22.
IacopinoAMDoxeyDCutlerCW. Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: Possible molecular mechanism of drug-induced gingival hyperplasia. J Periodontol.1997;68:73–83.
23.
EmingilGCokerIAtillaGHuseyinovA. Levels of Leukotriene B4 and platelet activating factor in gingival crevicular fluid in renal transplant patients receiving cyclosporine A. J Periodontol.2000;71:50–57.
24.
SeymourRASmithDG. The effect of plaque control programme on the incidence and severity of cyclosporin-induced gingival changes. J Clin Periodontol.1991;18:107–110.
25.
O'NeilTC. The effects of chlorhexidine and mechanical methods of plaque control on the recurrence of gingival hyperplasia in young patients taking phenytoin. Br Dent J.1982;152:130–133.
26.
CiancioGCBartzNWJrLaucielloFR. Cyclosporine-induced gingival hyperplasia and chlorhexidine: A case report. Int J Periodontics Restorative Dent.1991;11:241–245.
27.
AdamsCKSFamiliPA. Study of the effects of the drug FK506 on gingival tissues. Transplant Proc.1991;23:3193–3194.
28.
NeuhausPPichmayrRWilliamsR. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet.1994;344:423–428.
29.
BasileCMarangiALMontanaroA. Tacrolimus and gingival hyperplasia (letter). Nephrol Dial Transplant.1998;13:2980–2981.
30.
ThorpMDeMattosABennettWBarryJNormanD. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation.2000;69:1218–1220.
31.
KohnleMLutkesPZimmermannUPhilippTHeemannU. Conversion from cyclosporine to tacrolimus in renal transplant recipients with gum hyperplasia. Transplant Proc.1999;31(suppl 7A):44S–45S.
32.
BurrowsLKnightRGenykYSchwartzBMoranVAnandR. Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients. Transplant Proc.1998;30:2030–2032.
33.
BusqueSDemersPSt-LouisG. Conversion from neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. Transplant Proc.1998;30:1247–1248.
34.
BaderGLejeuneSMessnerM. Reduction of cyclosporine-induced gingival overgrowth following a change to tacrolimus: A case history involving a liver transplant patient. J Periodontol.1998;69:729–732.
35.
CecchinEZanelloFDe MarchiS. Treatment of cyclosporine-induced gingival hypertrophy. Ann Intern Med.1997;126:409–410.
36.
WongWHodgeMGLewisASharpstonePKingswoodJC. Resolution of cyclosporin-induced gingival hypertrophy with metronidazole. Lancet.1994;343:986.
37.
AufrichtCHoganELEttengerRB. Oral metronidazole does not improve cyclosporine A-induced gingival hyperplasia. Pediatr Nephrol.1997;11:552–555.
38.
WahlstromEZamoraJUTeichmanS. Improvement in cyclosporine-associated gingival hyperplasia with azithromycin therapy. N Engl J Med.1995;332:753–754.
39.
BoranMGunesZDorukFGonencFCetinS. Improvement in cyclosporine A associated gingival hyperplasia with azithromycin therapy. Transplant Proc.1996;28:2316.
40.
PuigJMLloverasJMBoschA. Treatment of gingival hyperplasia secondary to cyclosporine by the new macrolide azithromycin. Transplant Proc.1997;29:2379–2380.
41.
WirnsbergerGHPfragnerRMauricAZachRBogiatzisAHolzerH. Effect of antibiotic treatment with azithromycin on cyclosporine A-induced gingival hyperplasia among renal transplant recipients. Transplant Proc.1998;30:2117–2119.
42.
GomezESanchez-NunezMSanchezJE. Treatment of cyclosporine-induced gingival hyperplasia with azithromycin. Nephrol Dial Transplant.1997;12:2694–2697.
43.
NashMMZaltzmanJS. Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients. Transplantation.1998;65:1611–1615.
44.
Sanchez-NunezMLGomezESanchezJEPortalCAlvarez-GrandeJ. Clarithromycin in the treatment of cyclosporin-associated gingival hyperplasia. Nephrol Dial Transplant.1997;12:2040–2041.
45.
FerrariSLGoffinEMouradMWallemacqPSquiffletJPPirsonY. The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation.1994;58:725–727.
46.
GomezESanchezJEAguadoSGrandeAlvarez J. Interaction between azithromycin and cyclosporin? [letter]Nephron.1996;73:724.
47.
SeftonAMMaskellJPBeightonD. Azithromycin in the treatment of periodontal disease: Effect on microbial flora. J Clin Periodontol.1996;23:998–1003.
48.
GlaudeRPSniderME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother.1990;34:1056–1060.
49.
PilloniACamargoPMCarereMCarranzaFAJr. Surgical treatment of cyclosporine A- and nifedipine-induced gingival enlargement: Gingivectomy versus periodontal flap. J Periodontol.1998;69:791–797.
50.
MattsonJSBlankenauRKeeneJJ. Use of an argon laser to treat drug-induced gingival overgrowth. J Am Dent Assoc.1998;129:78–83.
51.
DarbarURHopperCSpeightPMNewmanHN. Combined treatment approach to gingival overgrowth due to drug therapy. J Clin Periodontol.1996;23:941–944.
52.
BothaPJ. Drug-induced gingival hyperplasia and its management: A literature review. J Dent Assoc S Afr.1997;52:659–664.
